ambroxol

Ligand id: 10692

Name: ambroxol

Structure and Physico-chemical Properties

2D Structure
Click here for structure editor
Calculated Physico-chemical Properties
Hydrogen bond acceptors 3
Hydrogen bond donors 3
Rotatable bonds 3
Topological polar surface area 58.28
Molecular weight 375.98
XLogP 2.9
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
In some jurisdictions ambroxol is used as an orally delivered expectorant drug [3]. It is not yet authorised for use by the FDA or the EMA (but is approved by individual European agencies). Clinical evaluation as an expectorant are ongoing for future US approval.
Ambroxol (as the hydrochloride) is being repurposed as a novel candidate for neurodegenerative diseases including Parkinson's disease (in particular in patients with defective β-glucocerebrosidase GBA1 genes [10,13]) [7,14] and amyotrophic lateral sclerosis (ALS; motor neurone disease; MND) [2,6]. Click here to link to ClinicalTrials.gov's full list of ambroxol studies. In July 2018, the EMA granted orphan designation for ambroxol hydrochloride to be used as a treatment for ALS/MND.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02914366 Ambroxol as a Treatment for Parkinson's Disease Dementia Phase 2 Interventional Lawson Health Research Institute
NCT03843541 A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions Phase 3 Interventional Zambon SpA
NCT02941822 Ambroxol in Disease Modification in Parkinson Disease Phase 2 Interventional University College, London